Intestinal microbes play an important role in the occurrence and development of metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver, and autoimmune diseases such as autoimmune liver disease, rheumatoid arthritis, and systemic lupus erythematosus. Targeting the gut microbiota for these diseases prevention is particularly attractive since it can use some approaches with high safety profiles and low risk of severe adverse effects, like probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), and antibiotics. Now, some studies have shown that regulating gut microbes can improve these diseases. However, it is still necessary to understand the mechanism of the regulation of the intestinal flora in the treatment of these diseases and to find the most appropriate treatment methods.
The goal of this Research Topic is to provide a forum to advance research on the use of probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), and antibiotics to treat metabolic and autoimmune diseases. We welcome manuscripts that deal with the following subtopics:
(1) The mechanisms underlying the effect of gut microbiota on promoting metabolic and autoimmune diseases occurrence, with the focus on key pathways such as bacterial dysbiosis, leaky gut, bacterial metabolites, and microorganism-related molecular patterns
(2) Construction of biomarkers for early diagnosis of metabolic and autoimmune diseases by gut microbiota
(3) Effect and mechanism of treating metabolic and autoimmune diseases by regulating gut microbiota
(4) The relationship between gut microbiota and the efficacy of some drugs for metabolic and autoimmune diseases
This Research Topic aims to collect publications relevant to human nutrition only. Studies on farm animals other than animal models for human nutrition will not be accepted in this Research Topic and will be re-directed to other relevant Frontiers journals.
Intestinal microbes play an important role in the occurrence and development of metabolic diseases such as obesity, type 2 diabetes, and non-alcoholic fatty liver, and autoimmune diseases such as autoimmune liver disease, rheumatoid arthritis, and systemic lupus erythematosus. Targeting the gut microbiota for these diseases prevention is particularly attractive since it can use some approaches with high safety profiles and low risk of severe adverse effects, like probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), and antibiotics. Now, some studies have shown that regulating gut microbes can improve these diseases. However, it is still necessary to understand the mechanism of the regulation of the intestinal flora in the treatment of these diseases and to find the most appropriate treatment methods.
The goal of this Research Topic is to provide a forum to advance research on the use of probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), and antibiotics to treat metabolic and autoimmune diseases. We welcome manuscripts that deal with the following subtopics:
(1) The mechanisms underlying the effect of gut microbiota on promoting metabolic and autoimmune diseases occurrence, with the focus on key pathways such as bacterial dysbiosis, leaky gut, bacterial metabolites, and microorganism-related molecular patterns
(2) Construction of biomarkers for early diagnosis of metabolic and autoimmune diseases by gut microbiota
(3) Effect and mechanism of treating metabolic and autoimmune diseases by regulating gut microbiota
(4) The relationship between gut microbiota and the efficacy of some drugs for metabolic and autoimmune diseases
This Research Topic aims to collect publications relevant to human nutrition only. Studies on farm animals other than animal models for human nutrition will not be accepted in this Research Topic and will be re-directed to other relevant Frontiers journals.
